Skip to main content
BSE
BSE Prices delayed by 5 minutes ! Prices as on   Oct 13, 2026 - 3:59PM   ABB India 6970.3 [ 1.47% ]ACC 1138 [ 1.16% ]Ambuja Cements 350.15 [ 0.37% ]Asian Paints 2360.9 [ 1.11% ]Axis Bank 1269 [ 1.04% ]Bajaj Auto 10249.15 [ 1.88% ]Bank of Baroda 237.6 [ 1.11% ]Bharti Airtel 1806.2 [ 1.59% ]Bharat Heavy 442 [ 0.64% ]Bharat Petroleum 286.8 [ 0.63% ]Britannia Industries 4802 [ 0.46% ]Cipla 1330 [ 1.24% ]Coal India 409 [ 1.14% ]Colgate Palm 1798 [ 1.58% ]Dabur India 379 [ 0.80% ]DLF 664 [ 2.31% ]Dr. Reddy's Lab. 1239.65 [ 0.74% ]GAIL (India) 168.4 [ 0.54% ]Grasim Industries 2919 [ 1.87% ]HCL Technologies 1321 [ 8.28% ]HDFC Bank 714.2 [ 1.41% ]Hero MotoCorp 4999.8 [ 1.50% ]Hindustan Unilever 1875.5 [ 2.94% ]Hindalco Industries 900.4 [ 1.77% ]ICICI Bank 1360.2 [ 1.13% ]Indian Hotels Co. 724 [ 1.69% ]IndusInd Bank 876 [ 2.71% ]Infosys 1062.2 [ 4.44% ]ITC 261.05 [ 1.34% ]Jindal Steel 1029.75 [ 0.76% ]Kotak Mahindra Bank 439 [ -0.90% ]L&T 3675 [ 1.24% ]Lupin 1960 [ 0.72% ]Mahi. & Mahi 2863 [ 1.69% ]Maruti Suzuki India 11254.9 [ -0.60% ]MTNL 24.08 [ -2.35% ]Nestle India 1331 [ 0.75% ]NIIT 84.6 [ 2.52% ]NMDC 71.45 [ 1.35% ]NTPC 311.3 [ 0.29% ]ONGC 222.5 [ 1.14% ]Punj. NationlBak 116.55 [ 0.47% ]Power Grid Corpn. 250.5 [ 0.50% ]Reliance Industries 1166.7 [ 0.66% ]SBI 955.9 [ 1.58% ]Vedanta 257 [ -2.93% ]Shipping Corpn. 281.35 [ 0.02% ]Sun Pharmaceutical 1769.1 [ 0.57% ]Tata Chemicals 629.45 [ -1.29% ]Tata Consumer 961 [ 0.31% ]Tata Motors Passenge 286 [ 0.67% ]Tata Steel 174.7 [ 1.39% ]Tata Power Co. 344.95 [ 0.51% ]Tata Consult. Serv. 2267 [ 6.59% ]Tech Mahindra 1542 [ 4.90% ]UltraTech Cement 10711 [ 1.49% ]United Spirits 1367.25 [ 1.32% ]Wipro 168.9 [ 4.52% ]Zee Entertainment 74.13 [ 0.19% ]

MARKETS

News Details

( As on 06/10/2026 09:48)

Lupin launches World’s First Fixed-Dose Triple Combination MDI for COPD

Lupin Limited has launched Formoflo-G® MDI, described by the company as the world’s first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI).

Formoflo-G® combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate in a single inhaler for the long-term management of moderate to severe COPD. The product is available in a fixed strength and is administered twice daily, offering patients a simplified treatment option.

Lupin said the launch expands its respiratory care portfolio and aims to address the treatment needs of millions of COPD patients in India. The company estimates that more than 55 million people in the country are living with COPD.

According to Lupin, the launch strengthens its position in respiratory care, where it ranks second in India’s respiratory therapy segment, based on IQVIA MAT March 2026 data. The company said the new therapy reflects its focus on developing differentiated and accessible treatment options for patients with respiratory diseases.